SG Americas Securities LLC Purchases 557,878 Shares of Edwards Lifesciences Corporation $EW

SG Americas Securities LLC raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2,757.1% in the third quarter, Holdings Channel reports. The fund owned 578,112 shares of the medical research company’s stock after buying an additional 557,878 shares during the quarter. SG Americas Securities LLC’s holdings in Edwards Lifesciences were worth $44,960,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in the business. Parkside Financial Bank & Trust boosted its stake in Edwards Lifesciences by 9.8% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 130 shares during the period. Prosperity Consulting Group LLC boosted its holdings in Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after purchasing an additional 132 shares during the period. NewSquare Capital LLC raised its position in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the last quarter. Empirical Finance LLC grew its holdings in shares of Edwards Lifesciences by 0.6% during the 2nd quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after purchasing an additional 134 shares in the last quarter. Finally, Alpine Bank Wealth Management increased its position in shares of Edwards Lifesciences by 10.7% during the third quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 135 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 1.2%

Shares of NYSE EW opened at $84.84 on Thursday. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The firm’s 50-day simple moving average is $84.98 and its 200 day simple moving average is $80.22. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The company has a market cap of $49.23 billion, a price-to-earnings ratio of 36.57, a price-to-earnings-growth ratio of 3.49 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm posted $0.67 earnings per share. The company’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. The trade was a 26.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 56,805 shares of company stock valued at $4,775,995. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. National Bankshares set a $92.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 31st. Barclays reaffirmed an “overweight” rating and set a $103.00 price objective (up from $99.00) on shares of Edwards Lifesciences in a report on Monday, December 8th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, October 8th. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Finally, JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $94.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.